Stay updated with breaking news from Daniel Vitt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...
Immunic Inc (NASDAQ:IMUX) has announced the publication of preclinical data highlighting the neuroprotective potential of its investigational drug,...
Issuer: Immunic, Inc. / Key word(s): Scientific publication Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis
Immunic Inc (NASDAQ:IMUX) president and CEO Dr Daniel Vitt joined Proactive's Stephen Gunnion with news of the publication of preclinical data confirming...
Jessica Breu: Good morning, and welcome to Immunic's First Quarter 2023 Earnings Call. My name is Jessica Breu, Head of Investor Relations and Communications at Immunic.